Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F13%3A33144114" target="_blank" >RIV/61989592:15310/13:33144114 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/13:33144114 RIV/00098892:_____/13:#0000494

Výsledek na webu

<a href="http://www.phytomedicinejournal.com/article/S0944-7113(13)00281-X/abstract" target="_blank" >http://www.phytomedicinejournal.com/article/S0944-7113(13)00281-X/abstract</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.phymed.2013.07.018" target="_blank" >10.1016/j.phymed.2013.07.018</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men

Popis výsledku v původním jazyce

The aim of this double-blind, placebo controlled clinical trial was to assess the effects of a combination of selenium and silymarin in men with lower urinary tract symptoms, benign prostatic hyperplasia and a prostate specific antigen (PSA) ?2.5ng/ml. The volunteers were randomized to two groups: the first one (n=26) received 240?g selenium (in the form of yeast l-selenomethionine) plus 570mg silymarin daily for 6 months and the second (n=29) received placebo. Outcome measures were changes in the International Prostate Symptom Score (IPSS), bladder volume (V), urinary flow rate, ultrasound estimated postvoid residual urine volume (RV), serum PSA, testosterone and selenium levels, safety clinical biochemistry, hematology and oxidative stress parametersat baseline and on day 180. The results showed statistically significant differences (p{0.05) between treatment and control groups for the following parameters: IPSS score, urodynamic parameters: maximal rate of urine flow (Qmax), averag

Název v anglickém jazyce

Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men

Popis výsledku anglicky

The aim of this double-blind, placebo controlled clinical trial was to assess the effects of a combination of selenium and silymarin in men with lower urinary tract symptoms, benign prostatic hyperplasia and a prostate specific antigen (PSA) ?2.5ng/ml. The volunteers were randomized to two groups: the first one (n=26) received 240?g selenium (in the form of yeast l-selenomethionine) plus 570mg silymarin daily for 6 months and the second (n=29) received placebo. Outcome measures were changes in the International Prostate Symptom Score (IPSS), bladder volume (V), urinary flow rate, ultrasound estimated postvoid residual urine volume (RV), serum PSA, testosterone and selenium levels, safety clinical biochemistry, hematology and oxidative stress parametersat baseline and on day 180. The results showed statistically significant differences (p{0.05) between treatment and control groups for the following parameters: IPSS score, urodynamic parameters: maximal rate of urine flow (Qmax), averag

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CE - Biochemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Phytomedicine

ISSN

0944-7113

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

75-81

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—